Suppr超能文献

咔唑和四氢咔啉衍生物作为具有多种抗精神病样特性的多巴胺 D 受体拮抗剂。

Carbazole and tetrahydro-carboline derivatives as dopamine D receptor antagonists with the multiple antipsychotic-like properties.

作者信息

Li Zhongtang, Fang Fan, Li Yiyan, Lv Xuehui, Zheng Ruqiu, Jiao Peili, Wang Yuxi, Zhu Guiwang, Jin Zefang, Xu Xiangqing, Qiu Yinli, Zhang Guisen, Li Zhongjun, Liu Zhenming, Zhang Liangren

机构信息

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou 221116, China.

出版信息

Acta Pharm Sin B. 2023 Nov;13(11):4553-4577. doi: 10.1016/j.apsb.2023.07.024. Epub 2023 Jul 27.

Abstract

Dopamine D receptor (DR) is implicated in multiple psychotic symptoms. Increasing the DR selectivity over dopamine D receptor (DR) would facilitate the antipsychotic treatments. Herein, novel carbazole and tetrahydro-carboline derivatives were reported as DR selective ligands. Through a structure-based virtual screen, ZLG-25 (DR  = 685 nmol/L; DR  > 10,000 nmol/L) was identified as a novel DR selective bitopic ligand with a carbazole scaffold. Scaffolds hopping led to the discovery of novel DR-selective analogs with tetrahydro--carboline or tetrahydro--carboline core. Further functional studies showed that most derivatives acted as hDR-selective antagonists. Several lead compounds could dose-dependently inhibit the MK-801-induced hyperactivity. Additional investigation revealed that and could decrease the apomorphine-induced climbing without cataleptic reaction. Furthermore, demonstrated unusual antidepressant-like activity in the forced swimming tests and the tail suspension tests, and alleviated the MK-801-induced disruption of novel object recognition in mice. Additionally, preliminary studies confirmed the favorable PK/PD profiles, no weight gain and limited serum prolactin levels in mice. These results revealed that provided potential opportunities to new antipsychotic drugs with the multiple antipsychotic-like properties.

摘要

多巴胺 D 受体(DR)与多种精神病症状有关。提高对多巴胺 D 受体(DR)的选择性将有助于抗精神病治疗。在此,报道了新型咔唑和四氢咔啉衍生物作为 DR 选择性配体。通过基于结构的虚拟筛选,ZLG-25(DR = 685 nmol/L;DR > 10,000 nmol/L)被鉴定为一种具有咔唑骨架的新型 DR 选择性双位点配体。骨架跳跃导致发现了具有四氢咔啉或四氢咔啉核心的新型 DR 选择性类似物。进一步的功能研究表明,大多数衍生物作为人 DR 选择性拮抗剂起作用。几种先导化合物可以剂量依赖性地抑制 MK-801 诱导的多动。进一步的研究表明,[具体化合物 1]和[具体化合物 2]可以减少阿扑吗啡诱导的攀爬行为而无僵住反应。此外,[具体化合物 3]在强迫游泳试验和悬尾试验中表现出不寻常的抗抑郁样活性,并减轻了 MK-801 诱导的小鼠新物体识别障碍。此外,初步研究证实了其良好的药代动力学/药效学特征,在小鼠中无体重增加且血清催乳素水平有限。这些结果表明,[具体化合物 3]为具有多种抗精神病样特性的新型抗精神病药物提供了潜在机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ac9/10638516/1527d9d6821f/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验